Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant

Transplant International

Volumn 24, Issue 10, 2011, Pages 991-998

  Truesdale, Aimee E ^a   Caldwell, Stephen H ^a   Shah, Neeral L ^a   Argo, Curtis K ^a   Al Osaimi, Abdullah M S ^a   Schmitt, Timothy M ^b   Northup, Patrick G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

cancer chemotherapy protocols; hepatoma; therapeutic chemoembolization; vascular endothelial growth factor

Indexed keywords

SORAFENIB;

ADULT; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; MORTALITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; PYRIDINES; TIME FACTORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 80052552460     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01299.x     Document Type: Article

References (28)

1. Llovet JM, Bruix J,. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl. 1): S20.
2. Roayaie K, Feng S,. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transpl 2007; 13 (11 Suppl. 2): S36.
3. Keating GM, Santoro A,. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378.
5. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293.
6. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) and common toxicity criteria (CTC). Available at:. Last access: December 21, 2010.
7. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783.
8. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25.
9. Finn RS,. Drug therapy: sorafenib. Hepatology 2010; 51: 1843.
10. Yoon DH, Ryoo BY, Ryu MH, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010; 40: 768.
11. Saab S, McTigue M, Finn RS, Busuttil RW,. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Exp Clin Transplant 2010; 8: 307.
12. Kim R, El-Gazzaz G, Tan A, et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010; 2: 62.
13. Saidi RF, Shah SA, Rawson AP, Grossman S, Piperdi B, Bozorgzadeh A,. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. Transplant Proc 2010; 42: 4582.
14. Vitale A, Volk ML, Pastorelli D, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010; 51: 165.
15. Vagefi PA, Hirose R,. Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy? J Gastrointest Cancer 2010; 41: 217.
16. Kamba T, McDonald DM,. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788.
17. Moser MA, Wall WJ,. Management of biliary problems after liver transplantation. Liver Transpl 2001; 7 (11 Suppl. 1): S46.
18. Pascher A, Neuhaus P,. Biliary complications after deceased-donor orthotopic liver transplantation. J Hepatobiliary Pancreat Surg 2006; 13: 487.
19. Fabris L, Cadamuro M, Libbrecht L, et al. Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. Hepatology 2008; 47: 719.
20. Gouw AS, van den Heuvel MC, Boot M, Slooff MJ, Poppema S, de Jong KP,. Dynamics of the vascular profile of the finer branches of the biliary tree in normal and diseased human livers. J Hepatol 2006; 45: 393.
21. van den Heuvel MC, de Jong KP, Boot M, Slooff MJ, Poppema S, Gouw AS,. Preservation of bile ductules mitigates bile duct loss. Am J Transplant 2006; 6: 2660.
22. Gaudio E, Barbaro B, Alvaro D, et al. Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. Am J Physiol Gastrointest Liver Physiol 2006; 291: G307.
23. Glaser SS, Gaudio E, Alpini G,. Vascular factors, angiogenesis and biliary tract disease. Curr Opin Gastroenterol 2010; 26: 246.
24. Gaudio E, Barbaro B, Alvaro D, et al. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 2006; 130: 1270.
25. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ,. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 2009; 50: 1861.
26. Kono N, Nakanuma Y,. Ultrastructural and immunohistochemical studies of the intrahepatic peribiliary capillary plexus in normal livers and extrahepatic biliary obstruction in human beings. Hepatology 1992; 15: 411.
27. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA,. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation 1993; 56: 69.
28. Hoffmann K, Glimm H, Radeleff B, et al. Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib(R) versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation-HeiLivCa [ISRCTN24081794]. BMC Cancer 2008; 8: 349.